Coya Therapeutics, Inc. KOL Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) featuring Dr. Stanley Appel (Houston Methodist Neurological Institute)

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.